



Cite this: Org. Biomol. Chem., 2013, 11,
3886
Received 18th March 2013,
Accepted 18th April 2013
DOI: 10.1039/c3ob40540k
www.rsc.org/obc
Determination of the binding epitope of RGD-
peptidomimetics to αvβ3 and αIIbβ3 integrin-rich
intact cells by NMR and computational studies†
Ileana Guzzetti,a Monica Civera,a Francesca Vasile,a Elena M. Araldi,a
Laura Belvisi,*a,b Cesare Gennari,a,b Donatella Potenza,*a,b Roberto Fanellic and
Umberto Piarullic
NMR experiments (transferred NOE and Saturation Transfer Diﬀerence) were used to shed light on the
binding epitope of RGD peptidomimetics 1–3 with integrins αvβ3 and αIIbβ3, expressed on the membrane
of ECV304 bladder cancer cells and human platelets, respectively. The NMR results were supported by
docking calculations of 1–3 in the active sites of αvβ3 and αIIbβ3 integrin receptors and were compared to
the results of competitive αvβ3 receptor binding assays and competitive ECV304 cell adhesion experi-
ments. While cis RGD ligand 1 interacts mainly with the α integrin subunit through its basic guanidine
group, trans RGD ligands 2 and 3 are able to interact with both the α and β integrin subunits via an elec-
trostatic clamp.
Introduction
The understanding of the interaction of a protein with its
ligands requires precise knowledge about the underlying recog-
nition events at a molecular level. A variety of biophysical
methods have been developed for this purpose and, recently,
several novel NMR spectroscopic techniques have emerged as
powerful tools to identify and characterize the binding epitope
of ligands to receptor proteins.1 Among these, transferred NOE
(tr-NOE) has gained momentum, as it provides the basis for a
variety of experimental protocols that are designed to detect
and characterize binding activity.2 The observation of tr-NOEs
relies on the diﬀerent behaviour of a small ligand molecule
free in solution rather than bound to a receptor protein. In
fact, a ligand bound to a large-molecular weight protein
behaves as a part of the large molecule and adopts the corres-
ponding NOE behaviour, showing strong negative NOEs, so-
called tr-NOEs. These tr-NOEs reflect the bound conformation
of the ligand. Binding of a ligand to a receptor protein can
thus easily be distinguished by looking at the sign and size of
the observed NOEs. A NMR spectroscopic technique, comp-
lementary to tr-NOE, is Saturation Transfer Diﬀerence
(STD).1b,3 This sequence helps identifying the group epitope,
revealing which moieties of the ligand molecule are closest to
the receptor in the bound state. The method is based on the
transfer of saturation from the protein to the bound ligand
which, by exchange, is released into solution where it is
detected. The degree of saturation of individual ligand protons
(expressed as absolute-STD percent) reflects their proximity to
the protein surface and can be used to describe the ligand–
target interactions.
Recently, our group has applied these methodologies using
intact tumor cells4 or platelets5 to investigate the ligand–recep-
tor interactions between azabicyclic lactam peptidomimetic
ligands containing the Arg–Gly–Asp (RGD) recognition
sequence and αvβ3 and αIIbβ3 integrin target proteins. Integrins
are a large family of transmembrane heterodimeric glyco-
protein receptors, composed of two non-covalently associated
α and β subunits.6 As a consequence of their role in important
physiological phenomena, integrin defects have been impli-
cated in many common diseases and some integrins have
become attractive targets for pharmacological intervention
under a number of pathological conditions.7 Many integrins,
including αvβ3, αvβ5, αIIbβ3 and α5β1, recognize the tripeptide
Arg–Gly–Asp (RGD) motif in their ligands. The observation
that αvβ3, αvβ5 and α5β1 integrin subtypes are essential for
tumor angiogenesis and can be successfully inhibited by
small-molecule ligands has turned them into attractive targets
for cancer research.8 Control of integrin activity is of crucial
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importance also in platelet aggregation. Indeed, ligand-
mimetic therapeutics that inhibit fibrinogen binding to αIIbβ3
are eﬀective in preventing and treating coronary artery throm-
bosis. Many peptide and peptidomimetic integrin ligands have
been developed, which contain the RGD tripeptide sequence
with diﬀerent flanking residues and three dimensional presen-
tation,9 and a few potent ligands are actually in diﬀerent
stages of clinical trials for cancer therapy, or in clinical use for
antithrombotic therapy.
Notwithstanding these recent achievements, the discovery of
new ligands displaying high activity and selectivity together with
an optimal pharmacological profile still remains a challenge in
this field. In this paper, we report the NMR investigations of the
interactions between the cyclic RGD peptidomimetic ligands
1–3 (Fig. 1)10 and intact ECV304 bladder cancer cells (in which
the integrin αvβ3 is overexpressed), and platelets (where αIIbβ3 is
predominant). The NMR data were interpreted with the aid of
docking calculations thus aﬀording an improved understanding
of ligand–integrin interactions.
Results and discussion
The cyclic peptidomimetics 1–3 expose the RGD sequence and
are characterized by bifunctional diketopiperazine scaﬀolds
that diﬀer for the configuration at C-3 and C-6 stereogenic
centres (Fig. 1). The diﬀerent configurations of the scaﬀolds
strongly influence the conformational preferences of the mole-
cules (vide infra). Studies by 1H-NMR experiments (VT-NMR
and NOESY) and Monte Carlo-Stochastic Dynamics (MC-SD)
simulations revealed that the ligands 1–3 display well-defined
preferred conformations featuring intramolecularly hydrogen-
bonded turn motifs stabilized by specific H-bonding pat-
terns.10a–c
To investigate the interaction of ligands 1–3 with integrins
αvβ3 and αIIbβ3, we performed tr-NOESY and STD NMR exper-
iments‡ with the ligands in a non-deuterated buﬀer suspension
of ECV304 bladder cancer cells and platelets, respectively. The
STD spectra of the three ligands 1–3 in the absence of cells did
not show any signal; in the presence of cells, an eﬃcient trans-
fer of saturation from the protons of the protein to the ligand
was obtained with a 3 second saturation time (60 gaussian
pulses, each of 50 ms).
Computational models for the interaction of RGD peptido-
mimetic ligands 1–3 with the αvβ3 integrin were built using
our previously developed docking approach,10b,c starting from
the X-ray structure of the extracellular segment of integrin αvβ3
complexed with the cyclic pentapeptide ligand Cilengitide
(Protein Data Bank entry 1L5G).11 In all the calculations, the
experimentally observed binding mode of Cilengitide with the
αvβ3 integrin was taken as a reference model for the analysis of
the docking results in terms of ligand–protein interactions. In
a similar way, starting from the crystal structure of the integrin
αIIbβ3 headpiece bound to the cyclic heptapeptide Eptifibatide,
currently in clinical use to prevent thrombosis (Protein Data
Bank entry 2VDN),12 a docking protocol was developed and
applied to study in silico the binding of ligands 1–3 to the
platelet integrin. The X-ray structures of αvβ3 and αIIbβ3 com-
plexed with RGD ligands have revealed an identical atomic
basis for the interaction: RGD binds to the interface of the α
and β subunits, the Arg residue fitting into a cleft in the α
subunit, and the Asp coordinating a cation in the β subunit.
The RGD tripeptide adopts a highly extended conformation
across the αvβ3 and αIIbβ3 integrin intersubunit interface. The
Arg and Asp side chains extend in opposite directions, and the
backbone in between is also extended. Looking at the dis-
tinguishing features, the basic ligand side chain must reach
further into the deeper β propeller pocket of αIIb to interact
with Asp224, whereas the residues Asp150 and Asp218 are
nearer in the shallower αV binding pocket.
Interactions with ECV304 bladder cancer cells
Compound 1. Investigation of the conformational prefer-
ences of ligand 1 in the free state by NMR and MC-SD analy-
sis10b,c revealed the presence of two main conformations: a
Gly–Asp β-turn conformation stabilized by a hydrogen bond
between DKP-NH10 and Arg–CvO (Fig. 2a), and an Arg–Gly
β-turn conformation stabilized by a hydrogen bond between
NHAsp and C(8)vO (Fig. 2b). The NOE experiments at 298 K
showed two mutually exclusive long-range NOE contacts
Fig. 1 Cyclic RGD-peptidomimetics 1–3 containing bifunctional DKP scaﬀolds.
Fig. 2 Preferred free state conformations of cis-DKP-RGD-peptidomimetic 1.
Arrows indicate signiﬁcant NOE contacts and dotted lines the hydrogen
bonding patterns stabilizing β-turn motifs: (a) Gly–Asp β-turn; (b) Arg–Gly β-turn
(bound conformation).
‡The spectra were performed on a Bruker Avance 600 MHz. Each sample was
prepared in a 3 mm NMR tube with 0.6 mg of a ligand and 6 × 106 cells in
200 μL of 20 mM phosphate buﬀer containing additionally 157 mM NaCl, 6 mM
KCl and 4 mM CaCl2.
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(positive): a cross-peak between DKP-NH10 and NHAsp (strong,
Fig. 2a), and a cross-peak between NHGly and NHAsp (medium,
Fig. 2b). The tr-NOESY experiment of compound 1 in the pres-
ence of ECV304 cells at 298 K also showed positive cross-
peaks, which indicate the absence of binding. Lowering the
temperature to 282 K, the NOESY spectrum of the free ligand 1
showed cross-peaks with an inverted phase, i.e. with the same
negative sign as the diagonal. The tr-NOESY spectrum per-
formed at 282 K showed a negative cross-peak between NHGly
(8.82 ppm) and NHAsp (8.13 ppm); this NOE contact is consist-
ent with the β-turn conformation at Arg–Gly stabilized by the
hydrogen bond between NHAsp and C(8)vO mentioned above
and depicted in Fig. 2b. This would indicate that, upon
binding to cells, the conformational equilibrium present in
the free state is shifted towards one conformation, and pre-
cisely to the less abundant in the free state (Fig. 2b).
To further prove this interaction, STD-NMR experiments
were performed in the presence of ECV304 cells at 282 K. In
these spectra, the region corresponding to the aromatic and
amide protons is well resolved and can be used to measure the
absolute intensity of STD (Fig. 3, blue bars). The largest STD
eﬀects (1.3% STD absolute intensity) were observed for the
guanidine NH protons (7.26 ppm), which are expected to be in
contact with the protein. Also the aromatic protons and the
DKP-NH1 showed an STD eﬀect (0.4 and 0.8% STD absolute
intensity, respectively) and consequently can be considered
lying close to the protein surface.
These results are in agreement with the docking analysis of
ligand 1 into the αvβ3 integrin binding site. Docking studies
starting from the bound conformation of compound 1
(Fig. 2b) produced top-ranked poses conserving optimal inter-
actions only between the positively charged Arg guanidinium
group of the ligand and the negatively charged side chains of
Asp218 and Asp150 in the α unit (Fig. 4). Probably, the short
Cβ(Arg)–Cβ(Asp) distance (<8 Å) of this geometry does not
allow the simultaneous superimposition of the guanidine and
carboxylic groups of the ligand with the corresponding moi-
eties of Cilengitide. In particular, the stabilizing hydrogen
bond interactions of Cilengitide carboxylate oxygen with the
backbone amides of Asn215 and Tyr122 in the β unit, and the
hydrogen bonds between Cilengitide backbone N–H and
protein backbone carbonyl groups in the β unit are missing in
the poses of compound 1. In contrast, the ligand benzyl group
is suitably positioned to interact with the aromatic moiety of
the β3-Tyr122, and the DKP-NH1 shows favourable van der
Waals contacts with the β3-Arg214 side chain (Fig. 4).
Compound 2. Conformational studies revealed that, in the
free state, ligand 2 adopts mainly one conformation characteri-
zed by the presence of a β-turn stabilized by a hydrogen bond
between NHGly and C(5)vO (Fig. 5), and by an extended
arrangement of the RGD sequence [Cβ(Arg)–Cβ(Asp) distance
of about 9 Å]. NOESY experiments showed a long range contact
(positive) between NHGly and NHArg, confirming this con-
formation.
The tr-NOESY experiments of compound 2 at 282 K showed
negative cross-peaks (i.e., with the same phase as the diag-
onal), indicating a binding situation. Moreover, the cross-
peaks between the aromatic protons and the Arg side chain
protons, which can be observed in the NOESY experiments
(free ligand), are lacking in the tr-NOESY spectrum (Fig. 6).
These cross-peaks suggest folding of the Arg-side chain, which
Fig. 4 Docking best pose of cis-DKP-RGD-peptidomimetic 1 (tube represen-
tation, C atoms in light blue, N in blue, O in red, H in white) into the crystal
structure of the extracellular domain of the αvβ3 integrin (α unit red and β unit
blue wire representation) overlaid on the bound conformation of Cilengitide
(gray tube representation). Only selected integrin residues involved in the inter-
actions with the ligand are shown. The metal ion at MIDAS is shown as a
magenta CPK sphere. For the sake of clarity, all H atoms bound to carbon are
omitted.
Fig. 5 Bound conformation of trans-DKP-RGD-peptidomimetic 2. Hydrogen
bond (dotted line) and NOE contact (arrow) are indicated.
Fig. 3 Relevant absolute STD percentages for the protons of cyclic DKP-RGD
1–3 obtained at T = 282 K in the presence of ECV304 cells: compound 1 (blue
bars), compound 2 (green bars), compound 3 (red bars).
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does not occur in the bound ligand. In fact, the formation of
the electrostatic clamp inside the binding pocket requires that
the side chains of Arg and Asp lie in an extended
conformation.
STD-NMR experiments in the presence of the cell suspen-
sion were performed both at 298 and 282 K (Fig. 7). At 298 K
the signals of DKP-NH1, NHAsp and NHGly overlap, and there-
fore it is diﬃcult to assess their involvement in the binding
process. The largest STD eﬀect is observed for the guanidine
NH protons (7.15 ppm, 2.3% STD absolute intensity). At 282 K
(see Fig. 3, green bars) the largest STD eﬀects are observed for
DKP-NH1 (0.8% STD absolute intensity) and for the guanidine
NH protons (7.26 ppm, 0.7% STD absolute intensity). The aro-
matic protons, DKP-NH10, NHGly and NHAsp, show similar STD
eﬀects (0.4, 0.4, 0.4 and 0.3%, respectively) and can also be
considered as lying close to the protein surface. Fig. 7 shows
the STD and 1H-NMR of ligand 2 at both temperatures (298
and 282 K). Temperature is an important parameter for the
sensitivity of STD spectroscopy;13 in fact, it strongly influences
the kinetics and the aﬃnity constant of protein–ligand
complex formation and, doing so, it aﬀects the observed STD
signals.
The signals observed in the STD spectrum confirm that
ligand 2 is in an extended conformation when binding to cells,
and it interacts closely with both the αv (by the guanidine
NHs) and β3 (by NHAsp, NHGly, DKP-NH10, DKP-NH1 and the
aromatic protons) subunits.
These results are in agreement with the docking analysis of
ligand 2 into the αvβ3 integrin binding site. In fact, docking
studies starting from the bound conformation of compound 2
(Fig. 5) produced top-ranked binding modes conserving all the
key polar interactions of the X-ray complex. The positively
charged guanidinium group of the ligand interacts with the
negatively charged carboxylates of Asp218 and Asp150 in the α
unit; one carboxylate oxygen of the ligand is coordinated to
the metal cation in the metal-ion-dependent adhesion site
(MIDAS) region of the β unit, while the second carboxylate
oxygen forms hydrogen bonds with the backbone amides of
Asn215 and Tyr122 in the β unit. A further stabilizing inter-
action involves the formation of a hydrogen bond between the
ligand backbone NH of the Asp residue and the backbone car-
bonyl group of Arg216 in the β unit (Fig. 8). Moreover, favour-
able van der Waals contacts can be detected between the
ligand benzyl group and the aromatic moiety of β3-Tyr122 and
the Hα of Ser123, between DKP-NH1 and the terminal methyl
protons of β3-Met180, between DKP-NH10 and the Hβ of Ser123
and the carbonyl group of Tyr122, and between NHGly and the
methyl protons of β3-Ala218.
Compound 3. Similarly to compound 2, the free state con-
formation of ligand 3 is characterized by a β-turn motif stabi-
lized by a hydrogen bond between NHGly and C(5)vO (Fig. 9),
as suggested by the relevant long-range NOE interaction
between NHGly and NHArg (positive at 298 K and negative at
282 K). In the tr-NOESY experiments at 298 K, the cross-peak
intensity is close to zero, while at 282 K the contacts are nega-
tive like in the free state.
Fig. 7 STD spectra, 1H-NMR spectra (selected regions) of ligand 2 at diﬀerent
temperatures. At T = 298 K, DKP-NH1, NHAsp and NHGly overlap.
Fig. 6 Left: NOESY spectrum of free compound 2 in non-deuterated buﬀer.
Right: tr-NOESY spectrum of compound 2 in a cell suspension, reﬂecting the
bound conformation. Experiments performed at T = 282 K.
Fig. 8 Docking best pose of trans-DKP-RGD-peptidomimetic 2 (tube represen-
tation, C atoms in green, N in blue, O in red, H in white) into the crystal structure
of the extracellular domain of an αvβ3 integrin (α unit red and β unit blue wire
representation) overlaid on the bound conformation of Cilengitide (gray tube
representation). Only selected integrin residues involved in the interactions with
the ligand are shown. The metal ion at MIDAS is shown as a magenta CPK
sphere. For the sake of clarity, all H atoms bound to carbon are omitted.
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Also for compound 3 STD-NMR experiments were per-
formed at two temperatures, 298 and 282 K. The experiment at
298 K showed quite large STD eﬀects for the guanidine NH,
NHAsp and NHGly (2.8, 2.0 and 2.1% STD absolute intensity,
respectively). When the temperature was lowered from 298 to
282 K, a decreased intensity of STD signals was observed. In
fact, at 282 K, the signals for the guanidine NH, NHAsp and
NHGly showed values of 1.2, 0.6 and 0.6% STD absolute inten-
sity, respectively. Additionally, at 282 K, the signals for the aro-
matic protons, HαGly and HβArg (0.3, 0.7 and 1.4% STD
absolute intensity, respectively), appeared in the STD spectrum
(see Fig. 3, red bars).
Docking calculations into the αvβ3 integrin binding site,
starting from the preferred RGD extended conformation
[Cβ(Arg)–Cβ(Asp) distance of about 9 Å] of ligand 3 (Fig. 9),
produced top-ranked binding modes conserving a good corres-
pondence with the receptor-bound structure of Cilengitide
and all the important polar interactions of the X-ray complex
already described for ligand 2. A relevant diﬀerence with the
interaction mode of ligand 2 is shown by the benzyl group of
ligand 3 which is placed between the side chains of β3-Arg214
and αv-Tyr178 (Fig. 10).
In vitro biological assays. Cyclic RGD peptidomimetics 1–3
were examined for their ability to compete with biotinylated
vitronectin for binding to the purified αvβ3 and αvβ5 recep-
tors.10b,c The IC50 values are collected in Table 1 together with
the value of the reference compound cyclo(RGDfV).
To assess the activity of compounds 1–3 as integrin anta-
gonists on a cell model, cell adhesion experiments were per-
formed using ECV304 bladder cancer cells, which overexpress
integrin αvβ3.4 Cells were allowed to adhere to immobilized
fibronectin or vitronectin in the presence of increasing concen-
trations of the tested compound. As shown in Table 2, cyclo-
[(3S,6S)DKP-RGD] 1 (cis) was not able to impair the adhesion
of the ECV304 cell line on either vitronectin or fibronectin,
thus confirming its low aﬃnity for the αvβ3 integrin. In con-
trast, both cyclic peptidomimetics 2 and 3 (trans) significantly
inhibited cell adhesion to either fibronectin or vitronectin,
exhibiting a micromolar anti-adhesive activity. These data
further demonstrate that the more extended RGD sequence
forced by the trans geometry of the diketopiperazine scaﬀolds
of compounds 2 and 3 (compared to a more folded RGD
sequence due to the cis geometry present in compound 1)
gives rise to a better pre-organization of the cyclic peptidomi-
metic for binding to the integrin receptors.10b,c
The micromolar activities obtained for compounds 2 and 3
in the ECV304 cell adhesion assay represent an ideal range for
testing interactions between the ligands and the integral mem-
brane protein of intact cells by means of tr-NOE and STD
experiments (vide supra).
Fig. 9 Bound conformation of trans-DKP-RGD-peptidomimetic 3. Hydrogen
bond (dotted line) and NOE contact (arrow) are indicated.
Table 1 Inhibition of biotinylated vitronectin binding to the αvβ3 and αvβ5
receptors
Ligand αvβ3 IC50 a [nM] αvβ5 IC50 a [nM]
1 3898 ± 418 >104
2 4.5 ± 1.1 149 ± 25
3 3.2 ± 2.7 114 ± 99
cyclo[RGDfV] 3.2 ± 1.3 7.5 ± 4.8
a IC50 values were calculated as the concentration of the compound
required for 50% inhibition of biotinylated vitronectin binding as
estimated by GraphPad Prism software. All values are the arithmetic
mean ± SD of triplicate determinations.
Fig. 10 Docking best pose of trans-DKP-RGD-peptidomimetic 3 (tube rep-
resentation, C atoms in pink, N in blue, O in red, H in white) into the crystal
structure of the extracellular domain of an αvβ3 integrin (α unit red and β unit
blue wire representation) overlaid on the bound conformation of Cilengitide
(gray tube representation). Only selected integrin residues involved in the inter-
actions with the ligand are shown. The metal ion at MIDAS is shown as a
magenta CPK sphere. For the sake of clarity, all H atoms bound to carbon are
omitted.
Table 2 Eﬀect of compounds 1–3 on ECV304 cell adhesion to vitronectin and
ﬁbronectin
Ligand Vitronectin IC50
a [μM] Fibronectin IC50 a [μM]
1 >200 >200
2 13.8 ± 0.2 2.2 ± 0.4
3 49.5 ± 3.0 15.0 ± 3.9
cyclo[RGDfV] 0.22 ± 0.00 0.36 ± 0.09
a Each data point was performed in triplicate in two independent
experiments.
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Interactions with platelets
Ligands 1–3 were subsequently analyzed in the presence of
platelets which, as already mentioned, express mainly integrin
αIIbβ3.
The tr-NOESY experiments at 298 K gave evidence of
binding for ligands 1 and 3. The conformational equilibrium
of compound 1 in the free state (Fig. 2) is apparently unaltered
upon binding to platelets. In the case of compound 3, the
cross-peaks between the aromatic protons and the Arg-side
chain protons, which can be observed in the NOESY experi-
ments (free ligand), are lacking in the tr-NOESY spectrum.
The absence of these cross-peaks in the bound state suggests
an extended conformation of the Arg-side chain, suitable for
the constitution of the electrostatic clamp. In the case of com-
pound 2, the experiment is inconclusive since the ligand cross
peak intensity was close to zero and the only detectable cross-
peaks were related to the platelet membrane.
The STD-NMR experiment on compound 1 in the presence
of the platelet suspension displayed signals for the guanidine
NH, DKP-NH1 and the aromatic protons (1.0, 0.6 and 0.3%
STD absolute intensity, respectively, see Fig. 11, blue bars).
These results highlight that compound 1 interacts through its
basic moiety with the αIIb subunit of integrin αIIbβ3. In the
case of ligand 2, the largest STD eﬀect is again observed for
the guanidine NH, and with a higher STD value (2.7% STD
absolute intensity, see Fig. 11, green bars); hence this proton
closely approaches the αIIb subunit of the protein. Remarkably,
also DKP-NH10, DKP-NH1, NHGly, NHAsp and the aromatic
protons of this ligand show quite intense STD eﬀects (2.3, 0.9,
0.8, 0.8 and 0.5%, respectively) and, as a consequence, ligand
2 can be considered as lying close to the protein surface.
A map of the STD signals obtained for ligand 2 in the pres-
ence of platelets and ECV cells (Fig. 12) shows that the same
protons in both the RGD sequence and the DKP scaﬀold
provide significant STD percentages and, as a consequence,
the epitope is conceivably the same.
The STD-NMR results in the presence of platelets are in
agreement with the docking analysis of ligand 2 into the αIIbβ3
integrin binding site. Docking studies starting from the bound
conformation of compound 2 (Fig. 5) produced top-ranked
binding modes conserving all the key interactions of the X-ray
complex between αIIbβ3 integrin and Eptifibatide (Fig. 13).12
The guanidine group of the ligand Arg forms a charged hydro-
gen bond to αIIb residue Asp224 as well as a hydrogen bond to
an αIIb backbone carbonyl (Phe160 or Tyr189). The carboxylate
of the ligand Asp side chain directly coordinates to the MIDAS
cation and is further stabilized by three hydrogen bonds to the
β3 backbone (Asn215, Tyr122 and Ser123) and one to the β3
Asn215 side chain. A further stabilizing interaction involves
the formation of a hydrogen bond between the ligand back-
bone NH of the Asp residue and the backbone carbonyl group
of Arg216 in the β3 unit. Moreover, favourable van der Waals
contacts can be detected between the ligand benzyl group and
the aromatic moiety of β3-Tyr122 and the Hα of Ser123,
between DKP-NH1 and the aromatic protons of αIIb-Phe160,
Fig. 11 Relevant absolute STD percentages for the protons of cyclic DKP-RGD
1–3 obtained at T = 298 K in the presence of a platelet suspension: compound
1 (blue bars), compound 2 (green bars), compound 3 (red bars).
Fig. 12 Binding epitopes: map of the STD signals of ligand 2 in the presence
of platelets (black squares) with respect to ECV cells (orange circles).
Fig. 13 Docking best pose of trans-DKP-RGD-peptidomimetic 2 (tube rep-
resentation, C atoms in green, N in blue, O in red, H in white) into the crystal
structure of the integrin αIIbβ3 headpiece (α unit red and β unit blue wire rep-
resentation) overlaid on the bound conformation of Eptiﬁbatide (gray tube rep-
resentation). Only selected integrin residues involved in the interactions with the
ligand are shown. The metal ion at MIDAS is shown as a magenta CPK sphere.
For the sake of clarity, all H atoms bound to carbon are omitted.
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between DKP-NH10 and the Hβ of Ser123, and between NHGly
and the methyl protons of β3-Ala218. It is worth noting that
these contacts have lower mean distance values in the docking
poses calculated for αIIbβ3 than in those found for αVβ3.
In the case of compound 3 the protons involved in the inter-
action with platelets belong to the DKP scaﬀold (DKP-NH1 and
DKP-H9, 1.0 and 0.4% STD absolute intensity, respectively) as
well as to the RGD sequence (NHGly, NHAsp and the guanidine
NH, 0.3, 0.3 and 1.1% STD absolute intensity, respectively),
while the aromatic protons do not appear to be in contact with
the protein. These signals are also observed in the interaction
with platelets of compound 2, and therefore the epitopes of
compounds 2 and 3 appear to be quite similar while binding to
platelets. A diﬀerent situation is found for the interaction of
ligand 3 with ECV304 tumour cells: here only the RGD protons
and the aromatic protons of the DKP benzyl group are involved,
while the protons of the DKP nucleus are not aﬀected by satu-
ration transfer from the protein (Fig. 14).
Docking calculations into the αIIbβ3 integrin binding site,
starting from the preferred RGD extended conformation of
ligand 3 (Fig. 9) produced top-ranked binding modes conser-
ving all the important polar interactions of the X-ray complex
with Eptifibatide already described for ligand 2. Favourable
van der Waals contacts can be detected between DKP-NH1 and
the Hβ of Ser123, between DKP-H9 and the aromatic protons
of β3-Tyr122, and between NHGly and the methyl protons of
β3-Ala218. A superimposition between the calculated interaction
mode of ligands 2 and 3 into the αIIbβ3 integrin binding site is
shown in Fig. 15.
Conclusions
NMR methodologies based on saturation transfer and detec-
tion of transferred NOEs have become powerful tools for the
determination of ligand–protein interactions and of the
binding epitopes. In this work, we have used these techniques
to shed light on the binding epitope of peptidomimetic integ-
rin ligands 1–3 in the interaction with living cells known to
express on their membrane integrins αvβ3 (ECV304 bladder
cancer cells) and αIIbβ3 (human platelets). The NMR results
were supported by docking studies and were compared to the
results of competitive αvβ3 receptor binding assays (Table 1)
and competitive ECV304 cell adhesion experiments (Table 2).
The ligands cyclo[DKP-RGD] 1–3 are cyclic peptidomimetics
containing the RGD sequence and chiral bifunctional diketopi-
perazine scaﬀolds, diﬀering for the configuration at C-3 and
C-6 stereogenic centres (Fig. 1). The scaﬀold stereochemistry
influences the conformation of the ligands both in the free
and in the cell-bound states. In particular, the (3S,6S)-configur-
ation of ligand 1 imparts a kinked conformation to the RGD
sequence which is reflected in the relatively short Cβ(Arg)–
Cβ(Asp) distance (<8 Å) and in its low binding aﬃnity to inte-
grin αvβ3, as witnessed by the high IC50 values in the competi-
tive receptor binding and cell adhesion assays. On the other
hand, the trans stereochemistry of the DKP side arms in
ligands 2 and 3 ensures an extended arrangement of the RGD
sequence [Cβ(Arg)–Cβ(Asp) distance of about 9 Å] which is well
suited for the αvβ3 and αIIbβ3 integrin receptors. This is
reflected in the high binding aﬃnity to the αvβ3 integrin recep-
tor and in the eﬃcient ECV304 cell adhesion inhibition dis-
played by these compounds.
The tr-NOE and STD experiments were run in the presence
of ECV304 bladder cancer cells and platelets. These exper-
iments helped identifying the binding epitopes of the peptido-
mimetics and defining the ligand–integrin bound con-
formations and the ligand–receptor interactions at a mole-
cular level. We have observed that (i) the primary interaction
between the ligand and the receptor is performed by the gua-
nidine residue of the arginine side chain (see behaviour of
peptidomimetic 1), (ii) the extended conformation of the trans
ligands 2 and 3 ensures the formation of the electrostatic
clamp (STD eﬀects on protons of the Arg and Asp residues),
(iii) the opposite configuration at C-3 and C-6 stereogenic
centres of the DKP scaﬀold of the trans ligands 2 and 3
induces a diﬀerent binding epitope for the non-RGD moiety of
the ligands (diketopiperazine and benzyl substituent). In par-
ticular, ligand 2 interacts with ECV304 and platelets through
Fig. 15 Docking best poses of trans-DKP-RGD-peptidomimetics 2 and 3 (green
and pink atom colour tube representation, respectively) into the crystal structure
of the integrin αIIbβ3 headpiece (α unit red and β unit blue wire representation).
Fig. 14 Binding epitopes: map of the STD signals of ligand 3 in the presence
of platelets (black squares) with respect to ECV cells (orange circles).
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the same binding epitope (see Fig. 12), whereas in the case of
ligand 3 a diﬀerent pattern of STD is observed (the DKP
moiety is involved only in the interaction with platelets, and
the benzyl group only with ECV cells, see Fig. 14). Finally,
these results are well modelled by docking analysis of 1–3 in
the active sites of αvβ3 and αIIbβ3 integrin receptors.
In conclusion, the combination of advanced NMR-techniques
and computational modelling represents a valuable tool for the
investigation of ligand–receptor interactions in living cells.
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